2. Search Result
Search Result
Results for "

hepatitis B surface antigen

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

6

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-126970
    HBF-0259

    		HBV Infection
    HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC50 of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis .
    HBF-0259
  • HY-133721
    Chamaechromone

    		HBV Infection Inflammation/Immunology
    Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses anti-hepatitis B virus (HBV) effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities .
    Chamaechromone
  • HY-171181
    ZINC20451377

    		HBV Infection
    ZINC20451377 is a small molecule targeting hepatitis B (HBV) surface antigen (HBsAg) and can effectively inhibit wild-type hepatitis B and tenofovir (HY-13910)-resistant hepatitis B .
    ZINC20451377
  • HY-145060
    HBV-IN-13

    		HBV Infection
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor. From patent WO2021204252A1, compound 1_B .
    HBV-IN-13
  • HY-P2783
    Destruxin B2

    		HBV Infection
    Destruxin B2 (compound 5) is a natural depsipeptide that can be inhibits hepatitis B surface antigen (HBsAg) secretion in Hep3B cells with an IC50 1.30 μM .
    Destruxin B2
  • HY-173278
    AIC263282

    		HBV Potassium Channel Infection
    AIC263282 is a potent Hepatitis B Virus (HBV) capsid assembly modulator with an EC50 of 3.8 nM. AIC263282 shows an IC50 of 61 nM for hERG. AIC263282 exhibits activity against viral replication and hepatitis B surface antigen (HBsAG) on primary human hepatocytes .
    AIC263282
  • HY-N3093
    Periglaucine B

    (+)-Periglaucine B

    		 HBV Infection
    Periglaucine B ((+)-Periglaucine B) is an alkaloid and an HBsAg inhibitor. Periglaucine B can be isolated from Pericampylus glaucus. Periglaucine B inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells with an IC50 of 0.47 mM .
    Periglaucine B
  • HY-145053
    HBV-IN-10

    		HBV Infection
    HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6 .
    HBV-IN-10
  • HY-159987
    AB-161

    		HBV Infection
    AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research .
    AB-161
  • HY-P4046
    HBV Seq2 aa:179-186

    		HIV Inflammation/Immunology
    HBV Seq2 aa:179-186 serve as effective motifs for CTL response in H-2b system after in vitro restimulation of the primed T cells. HBV Seq2 aa:179-186 is a novel epitope identified on the surface antigen of hepatitis B virus .
    HBV Seq2 aa:179-186
  • HY-W754691
    Glaziovine

    		HBV Infection
    Glaziovine is an antiviral agent found in Hypserpa nitida. Glaziovine exhibits significant inhibitory activity against HBV, capable of suppressing hepatitis B virus surface antigen (HBsAg) secretion in Hep G2.2.15 cells transfected with HBV, with an IC50 of 8 nM .
    Glaziovine
  • HY-145052
    HBV-IN-9

    		HBV Infection
    HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC50=10 nM) and HBV DNA production inhibitor (IC50=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.
    HBV-IN-9
  • HY-P99541
    Tuvirumab

    anti-hepatitis B; OST 577; SDZ-OST 577

    		 HBV Infection
    Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
    Tuvirumab
  • HY-N12105
    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside

    		HBV Infection
    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC50 values of 1.67 and >2.15 mM, respectively .
    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside
  • HY-N0854
    Alisol F

    		HBV Infection
    Alisol F is a triterpene isolated from Alisma orinentale, has immunosuppressive and anti-virus functions. Alisol F exhibits inhibitory activity in vitro on hepatitis B virus (HBV) surface antigen (HBsAg) secretion of the HepG2.2.15 cell line with an IC50 of 0.6 μM .
    Alisol F
  • HY-145053A
    (5S,8R)-HBV-IN-10

    		HBV Infection
    (5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6 .
    (5S,8R)-HBV-IN-10
  • HY-145713
    GS-8873

    HBV-IN-19

    		 HBV Infection
    GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys .
    GS-8873
  • HY-P990015
    Tobevibart

    VIR-3434

    		 HBV Infection
    Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda1, Isotype Control (HY-P99992) .
    Tobevibart
  • HY-145059
    HBV-IN-12

    		HBV Infection
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15 .
    HBV-IN-12
  • HY-145713A
    GS-8873 TFA

    HBV-IN-19 TFA

    		 HBV Infection
    GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713). GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys .
    GS-8873 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: